Breast cancer screening and diagnostic company BCAL Diagnostics (ASX:BDX) has appointed a new Australian based CEO, Shane Ryan to launch the company’s new test BREASTEST and drive the commercialisation process.
Mr Ryan was initially appointed as the company’s Chief Operating Officer in Q1 FY24 and has clearly demonstrated that he will be the right leader to take the organisation through market launch, and to ensure expansion and growth of the business.
He has an excellent track record of success and brings a wealth of biotechnology product commercialisation experience from his prior role as Global SVP of Strategy & Innovation - Patient Access at GenesisCare.
In 2021 he brought to market a test for breast cancer patients which was successfully launched in Australia and is now available nationwide. Shane’s commercial, product launch experience will be vital in BREASTEST in late 2024.
Current CEO, Dr John Hurrell will become a Non-Executive Director, and consultant to the Company providing ongoing advice in relation to the scientific product development, laboratory scaling, and commercial operations, as well as preparing for a subsequent launch in the USA.
“I am delighted to welcome Shane as our new CEO at this incredibly exciting and important time for the company. The commercial launch of BREASTEST is fast approaching and Australia is our priority market in the short term,” BCAL Diagnostics Chair, Jayne Shaw, said.
“We have reached an inflection point and we are confident in Shane’s ability to successfully execute our strategic growth strategy in the lead up to and beyond launch later this year.
“I would also like to express our thanks to John Hurrell who has made a significant contribution to BCAL. John’s vast leadership experience in biotechnology, passion and drive for improving outcomes for cancer patients has been invaluable and I look forward to his continued involvement as a Director of and consultant to the company.”
These leadership changes follow the appointment of commercial leader David Darling as Non-Executive Director announced on 29 February 2024 and the formation of a highly credentialed Clinical Advisory Board in early FY24.
“It has been a priority of the Board to ensure BCAL is in the best possible position to execute its strategy and we have full confidence in the team to do so. BCAL has now cemented its position as a fast-emerging player in the breast cancer diagnostics sector and the next 12 months will be critical to ensuring we continue delivering at the same momentum,” Shaw said.